scholarly journals A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

2017 ◽  
Vol 6 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Yingzhu Chen ◽  
Shuai Lu ◽  
Hao Jia ◽  
Yao Deng ◽  
Jianfang Zhou ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Spike Protein ◽  
Terminal Domain ◽  
Neutralizing Monoclonal Antibody ◽  
Antibody Targeting

scholarly journals A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein

2017 ◽  
Vol 6 (1) ◽  
pp. 1-1 ◽  
Author(s):  
Yingzhu Chen ◽  
Shuai Lu ◽  
Hao Jia ◽  
Yao Deng ◽  
Jianfang Zhou ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Spike Protein ◽  
Terminal Domain ◽  
Neutralizing Monoclonal Antibody ◽  
Antibody Targeting

scholarly journals The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-World Setting

2021 ◽  
Author(s):  
Douglas S Corwin ◽  
Peter T Ender ◽  
Nitasa Sahu ◽  
Ryan A Durgham ◽  
Dennis M McGorry ◽  
...  
Keyword(s):  
Emergency Department ◽  
Monoclonal Antibody ◽  
High Risk ◽  
Real World ◽  
Hospital Admissions ◽  
Emergency Department Visits ◽  
Spike Protein ◽  
Ambulatory Treatment ◽  
Real World Setting ◽  
Antibody Targeting

Abstract Bamlanivimab, a monoclonal antibody targeting the spike protein of SARS-CoV-2, is available for ambulatory treatment of COVID-19. This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.

scholarly journals Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2 Infected Syrian Hamsters

2020 ◽  
Author(s):  
Rebecca L. Brocato ◽  
Lucia M. Principe ◽  
Robert K. Kim ◽  
Xiankun Zeng ◽  
Janice A. Williams ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Animal Models ◽  
Adaptive Immunity ◽  
Protective Efficacy ◽  
Severe Disease ◽  
Clinical Signs ◽  
Spike Protein ◽  
Syrian Hamsters ◽  
Viral Loads ◽  
Neutralizing Monoclonal Antibody

AbstractAnimal models recapitulating human COVID-19 disease, especially with severe disease, are urgently needed to understand pathogenesis and evaluate candidate vaccines and therapeutics. Here, we develop novel severe disease animal models for COVID-19 involving disruption of adaptive immunity in Syrian hamsters. Cyclophosphamide (CyP) immunosuppressed or RAG2 knockout (KO) hamsters were exposed to SARS-CoV-2 by the respiratory route. Both the CyP-treated and RAG2 KO hamsters developed clinical signs of disease that were more severe than in immunocompetent hamsters, notably weight loss, viral loads, and fatality (RAG2 KO only). Disease was prolonged in transiently immunosuppressed hamsters and uniformly lethal in RAG2 KO hamsters. We evaluated the protective efficacy of a neutralizing monoclonal antibody and found that pretreatment, even in immunosuppressed animals, limited infection. Our results suggest that functional B and/or T cells are not only important for the clearance of SARS-CoV-2, but also play an early role in protection from acute disease.One Sentence SummaryAn antibody targeting the spike protein of SARS-CoV-2 limits infection in immunosuppressed Syrian hamster models.

scholarly journals A Neutralizing Monoclonal Antibody Targeting the Acid-Sensitive Region in Chikungunya Virus E2 Protects from Disease

2013 ◽  
Vol 7 (9) ◽  
pp. e2423 ◽  
Author(s):  
Suganya Selvarajah ◽  
Nicole R. Sexton ◽  
Kristen M. Kahle ◽  
Rachel H. Fong ◽  
Kimberly-Anne Mattia ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Chikungunya Virus ◽  
Sensitive Region ◽  
Neutralizing Monoclonal Antibody ◽  
Antibody Targeting

Neutralizing Monoclonal Antibody: New Member of Therapeutic Armamentarium Against COVID-19

2021 ◽  
Vol 11 (Number 2) ◽  
pp. 78-87
Author(s):  
Z H M Nazmul Alam ◽  
Ishrat Tahsin
Keyword(s):  
Monoclonal Antibody ◽  
Recombinant Proteins ◽  
Risk Groups ◽  
Target Population ◽  
Spike Protein ◽  
Passive Immunotherapy ◽  
Neutralizing Monoclonal Antibody ◽  
Optimal Deployment ◽  
Clinical Questions ◽  
New Treatments

Many targeted treatment methods have focused on SARS-CoV-2's spike protein, along with neutralizing monoclonal antibodies (mAbs), which are recombinant proteins, may be employed as a kind of passive immunotherapy to reduce pathogenicity. While vaccines are still the best way to prevent COVID-19 infection, mAbs are an effective treatment for those who have already been infected, as well as having the potential to prevent infection in those who have already been exposed to SARS-CoV-2, which can be especially beneficial to certain high-risk groups. Due to the limited initial availability of these new treatments, it is essential to consider their larger potential and create methods for their optimal deployment in clinical practice. The objectives of this review is to answer the most commonly asked clinical questions from HCPs and patients about the target population, dose, interactions with other medicines and vaccines, duration of immunity, and variants.

scholarly journals pH-Induced Conformational Change of the Rotavirus VP4 Spike: Implications for Cell Entry and Antibody Neutralization

2005 ◽  
Vol 79 (13) ◽  
pp. 8572-8580 ◽  
Author(s):  
Joseph B. Pesavento ◽  
Sue E. Crawford ◽  
Ed Roberts ◽  
Mary K. Estes ◽  
B. V. Venkataram Prasad
Keyword(s):  
Monoclonal Antibody ◽  
Sialic Acid ◽  
Conformational Change ◽  
Cell Entry ◽  
Spike Protein ◽  
Cell Binding ◽  
Ph Changes ◽  
Multiple Receptors ◽  
Neutralizing Monoclonal Antibody ◽  
Dependent Cell

ABSTRACT The rotavirus spike protein, VP4, is a major determinant of infectivity and neutralization. Previously, we have shown that trypsin-enhanced infectivity of rotavirus involves a transformation of the VP4 spike from a flexible to a rigid bilobed structure. Here we show that at elevated pH the spike undergoes a drastic, irreversible conformational change and becomes stunted, with a pronounced trilobed appearance. These particles with altered spikes, at a normal pH of 7.5, despite the loss of infectivity and the ability to hemagglutinate, surprisingly exhibit sialic acid (SA)-independent cell binding in contrast to the SA-dependent cell binding exhibited by native virions. Remarkably, a neutralizing monoclonal antibody that remains bound to spikes throughout the pH changes (pH 7 to 11 and back to pH 7) completely prevents this conformational change, preserving the SA-dependent cell binding and hemagglutinating functions of the virion. A hypothesis that emerges from the present study is that high-pH treatment triggers a conformational change that mimics a post-SA-attachment step to expose an epitope recognized by a downstream receptor in the rotavirus cell entry process. This process involves sequential interactions with multiple receptors, and the mechanism by which the antibody neutralizes is by preventing this conformational change.

Sign in / Sign up

Export Citation Format

Share Document